Dupilumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases

Q4 Medicine

Voprosy Sovremennoi Pediatrii - Current Pediatrics Pub Date : 2023-11-06 DOI:10.15690/vsp.v22i5.2622

Nikolay N. Murashkin, Leonid A. Opryatin, Ekaterina S. Pavlova, Roman V. Epishev, Alexandr I. Materikin, Roman A. Ivanov, Alena A. Savelova, Maria A. Leonova

{"title":"Dupilumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases","authors":"Nikolay N. Murashkin, Leonid A. Opryatin, Ekaterina S. Pavlova, Roman V. Epishev, Alexandr I. Materikin, Roman A. Ivanov, Alena A. Savelova, Maria A. Leonova","doi":"10.15690/vsp.v22i5.2622","DOIUrl":null,"url":null,"abstract":"Background . Atopic dermatitis (AD) manifests during the first year of life in majority of all cases. The early disease onset is associated with the development of comorbid atopic conditions within the «atopic march» phenomenon. The AD pathogenesis is associated with genetic predisposition, epidermal barrier dysfunction, and immune dysregulation. T2-inflammation specifically determines the entire immune cascade of inflammatory reactions, and, thus, dictates the need of early drug intervention to modify the disease course. Clinical case description. This article presents two clinical cases of severe AD in children under 6 years of age. The treatment of both cases included genetically engineered biologic drug dupilumab. Continuous therapy for 4–5 months made it possible to relieve the skin manifestations of the disease. Conclusion . AD, manifesting in infancy, is associated with high risk of developing other atopic spectrum diseases in older age. The timely onset of biological therapy allows us to affect immune dysregulation, and thereby to prevent the comorbid atopic conditions development.","PeriodicalId":37561,"journal":{"name":"Voprosy Sovremennoi Pediatrii - Current Pediatrics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy Sovremennoi Pediatrii - Current Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15690/vsp.v22i5.2622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background . Atopic dermatitis (AD) manifests during the first year of life in majority of all cases. The early disease onset is associated with the development of comorbid atopic conditions within the «atopic march» phenomenon. The AD pathogenesis is associated with genetic predisposition, epidermal barrier dysfunction, and immune dysregulation. T2-inflammation specifically determines the entire immune cascade of inflammatory reactions, and, thus, dictates the need of early drug intervention to modify the disease course. Clinical case description. This article presents two clinical cases of severe AD in children under 6 years of age. The treatment of both cases included genetically engineered biologic drug dupilumab. Continuous therapy for 4–5 months made it possible to relieve the skin manifestations of the disease. Conclusion . AD, manifesting in infancy, is associated with high risk of developing other atopic spectrum diseases in older age. The timely onset of biological therapy allows us to affect immune dysregulation, and thereby to prevent the comorbid atopic conditions development.

查看原文本刊更多论文

Dupilumab治疗6岁以下儿童严重特应性皮炎的疗效和安全性:2例临床病例

背景。特应性皮炎(AD)在大多数情况下表现在生命的第一年。在“特应性行军”现象中，疾病的早期发病与共病特应性疾病的发展有关。AD的发病机制与遗传易感性、表皮屏障功能障碍和免疫失调有关。t2炎症特异性地决定了炎症反应的整个免疫级联反应，因此，需要早期药物干预来改变疾病进程。临床病例描述。本文报道两例6岁以下儿童重度AD的临床病例。这两个病例的治疗包括基因工程生物药物杜匹单抗。持续治疗4-5个月，可以缓解疾病的皮肤表现。结论。阿尔茨海默病表现于婴儿期，与老年时发生其他特应性谱系疾病的高风险相关。及时的生物治疗使我们能够影响免疫失调，从而防止共病的特应性疾病的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Voprosy Sovremennoi Pediatrii - Current Pediatrics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

0.70

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The main purpose of the academic journal "Current Pediatrics" is to cover the issues related to health, emotional state, and social adaptation of children. In the journal we publish the most pressing issues of research and applied problems (such as social paediatrics; clinical findings, anamnesis, and diagnosis of paediatric diseases; prevention and rehabilitation; supply of healthy and sick child), reviews on the current state of medical science and management of health care in Russia. Along with the concern for providing a high level of basic research publications, the journal, being a mass media tool, tends to meet the interests and requirements of practitioners from different regions and bring up vital and urgent questions. To accomplish this purpose the journal includes the materials of practical interest presented in the following sections: "Exchange of experience", "Doctor''s aid", "Continuous professional education", "Expert Opinion". The journal presents actual official information from the Union of Paediatricians of Russia and publishes materials on the history of medical science, congresses, seminars, conferences, both in our country and abroad.